Ready-to-Use Cardiac Organoids

Reliable efficacy validation and safety assessment are essential for advancing drug candidates with confidence. However, conventional preclinical models do not always provide the human-relevant insights needed to accurately predict cardiac risk before clinical development.

As the demand for more predictive safety evaluation continues to grow, 3D human-relevant models are becoming increasingly important. Compared with traditional 2D cultures and animal models, human iPSC-derived cardiac organoids better reflect the structural organization, multicellular complexity, and functional characteristics of human cardiac tissue.

As part of New Approach Methodologies (NAMs), cardiac organoid-based platforms provide a powerful tool to support drug-induced cardiotoxicity assessment, helping researchers generate more relevant data, improve predictive accuracy, and make better decisions earlier in drug development.

Product Introduction

Human cardiac organoids provide a physiologically relevant 3D platform for drug discovery and cardiac safety assessment. Yet in-house model establishment can be technically demanding, requiring specialized expertise, complex differentiation workflows, extended culture timelines, and rigorous process control.

ACROBiosystems' Ready-to-Use Cardiac Organoids are designed to overcome these barriers by providing an accessible, quality-controlled model with characterized functional performance, helping researchers accelerate assay development and generate high-value data with greater efficiency.

Product List
Cat. No. Product Description Product Size
CIPO-HWL01 Ready-to-use hiPSC-Derived Cardiac Organoids 5 /20 /100 organoids
RIPO-HWM01 hiPSC-Derived Cardiac Organoid Maintenance Kit 80 / 220 mL

*To support drug discovery and safety assessment, ACROBiosystems offers Microelectrode Array (MEA)-based functional testing service for evaluating electrophysiological activity and drug-induced functional responses. Additional readouts, including calcium imaging, immunostaining, ELISA, qPCR, and customized analyses, can also be provided based on project needs and feasibility.

Product Advantages
Ready-to-Use and Easy to Operate
No additional differentiation required, eliminating the need for complex induction and long-term culture
Simple recovery after receipt saves time and resources
Biomimetic Human Cardiac Microenvironment
Self-assembles into chamber-like 3D cardiac structures
Contains key cardiac cell types, including cardiomyocytes, fibroblasts, endothelial cells, and smooth muscle cells
Stable Functional Performance for Safety Assessment
Enables detection of spontaneous beating, electrical activity, and related functional phenotypes
Provides reproducible functional readouts for cardiac safety evaluation
Multi-Level QC Framework Ensures Batch Consistency & Reliable Data
Strong inter-batch consistency in morphology, marker expression, and functional phenotypes
Controlled intra-batch variability, with consistent organoid size, beating behavior, and phenotypic characteristics
Applications
Drug Screening
Cardiotoxicity Assessment
Disease Modeling
Basic Research

Resources

Operating Videos

FAQ

Q

What are ready-to-use cardiac organoids?

ACROBiosystems' ready-to-use cardiac organoids are three-dimensional cardiac tissue models derived from human induced pluripotent stem cells (iPSCs) through standardized differentiation and culture processes. Eliminating the complexity of in-house iPSC differentiation and organoid generation, these pre-manufactured organoids are ready for downstream experiments following a simple recovery and culture process using the dedicated maintenance kit, helping researchers reduce the time and effort required for model preparation.
Q

What are the differences between cardiac organoids and 2D cardiomyocyte cultures?

While the conventional 2D cultures consist of a monolayer of cardiomyocytes, cardiac organoids feature a three-dimensional structure comprising multiple cardiac lineages, including cardiomyocytes, fibroblasts, endothelial cells, and smooth muscle cells. These self-organizing models also develop chamber-like structures and exhibit spontaneous beating. By capturing this multicellular 3D microenvironment, cardiac organoids can support the study of cell-cell interactions and tissue-level functional responses before and after drug treatment, such as beating rate, rhythm, and field potential, making them useful for the prediction of drug-induced cardiotoxicity and safety assessment.
Q

How is the maturity of cardiac organoids evaluated?

The maturity of cardiac organoid is typically evaluated based on three dimensions: cellular composition, structural characteristics, and functional performance. Key indicators include specific markers for cardiomyocytes (e.g., cTnT), stromal or endothelial lineages (e.g., VIM and CD31), as well as functional readouts such as spontaneous beating rate and rhythm, calcium transients, and electrophysiological activity. Together, complementary analytical methods, including immunofluorescence, calcium imaging, and microelectrode array (MEA) analysis, provide a comprehensive framework to profile the mature tissue architecture and functional status of cardiac organoids.
Q

How can cardiac organoids be used to assess drug-induced cardiotoxicity?

Cardiac organoids offer a robust platform to assess drug-induced cardiotoxicity through multiple functional and cellular injury endpoints. Experimental workflows typically begin with baseline measurements, followed by concentration-dependent drug exposure and appropriate controls. By integrating real-time functional readouts, such as beating rate, rhythm, field potential duration (FPD/FPDc), and calcium transients, with cytotoxicity assays (e.g. ATP, LDH, and apoptosis metrics), researchers can capture a comprehensive profile of potential drug-induced cardiac effects.
Q

How can reproducibility be improved in cardiac organoid-based drug testing?

Reproducibility in cardiac organoid-based assays can be affected by variables such as organoid-differentiation protocols, culture conditions, and baseline functional characteristics. Using standardized models alongside consistent handling and maintenance conditions can help mitigate variability. Selecting cardiac organoids charaterized by stable growth patterns, consistent morphology and uniform size can further improve comparability across batches and experimental replicates. ACROBiosystems' ready-to-use cardiac organoids demonstrate a low intra-batch diameter coefficient of variation (CV). Furthermore, batch-specific Certificates of Analysis (COAs) are available on our website by lot number, supporting model consistency assessment.
  • Background
  • Product Introduction
  • Resources
  • Operating Videos
  • FAQ